VNDA — Vanda Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1347178 ·
Last close
$5.10
Market Cap
$306.69M
52W High
$7.74
52W Low
$4.94
ADV30
864,433
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 51,718,000 | 48,559,000 | -50,224,000 | -48,567,000 | 433,525,000 | 54,034,000 | 152,760,000 |
| Dec 2025 | 57,216,000 | 53,383,000 | -40,353,000 | -141,187,000 | 488,948,000 | 84,851,000 | 161,762,000 |
| Sep 2025 | 56,258,000 | 53,304,000 | -31,284,000 | -22,586,000 | 601,140,000 | 70,022,000 | 135,141,000 |
| Jun 2025 | 52,590,000 | 49,854,000 | -38,503,000 | -27,207,000 | 624,746,000 | 80,983,000 | 138,417,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-109,442,000
Investing CF
$94,860,000
Financing CF
$-2,906,000
CapEx
$-998,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.73
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-394,766,000
Inventory
$1,852,000
Receivables
$54,578,000
ST Investments
$178,996,000
EBIT TTM
$-151,168,000
Pretax Income TTM
$-138,647,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$217,782,000
EBITDA
$-151,976,992
Free Cash Flow
$-83,154,496
Enterprise Value
$117,454,368
Total Cash
$202,310,000
Total Debt
$13,073,000
Shares Out
60,135,562
Trailing EPS
$-4.06
Book Value
$5.54
ROE
-60.5%
ROA
-18.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 216,105,000 | -151,168,000 | -220,474,000 | 488,948,000 | 161,762,000 | — | -109,442,000 |
| Dec 2024 | 198,772,000 | -40,660,000 | -18,900,000 | 656,204,000 | 117,658,000 | — | -15,757,000 |
| Dec 2023 | 192,640,000 | -13,952,000 | 2,509,000 | 648,440,000 | 103,530,000 | — | 12,801,000 |
| Dec 2022 | 254,382,000 | 6,329,000 | 6,275,000 | 634,247,000 | 107,049,000 | — | 31,984,000 |
TTM Snapshot
Revenues TTM
$210,264,000
NetIncome TTM
$108,991,000
OpCashFlow TTM
$0
Assets (Latest)
$533,456,000
Forward EPS
$0.20
Max Pain — expiry 2026-12-18
max pain strike: $5.00 · spot: $5.10 · call oi: 4,718 · put oi: 923
Expected Move to 2026-12-18:
±$2.35
(46.08%) —
implied range
$2.75 –
$7.45
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IRD | Opus Genetics, Inc. | $306.32M | $3.71 | — |
| ORGO | Organogenesis Holdings Inc. | $304.96M | $2.37 | — |
| LYEL | Lyell Immunopharma, Inc. | $301.94M | $12.94 | — |
| AMRN | AMARIN CORP PLC\UK | $299.02M | $14.26 | — |
| PRLD | Prelude Therapeutics Inc | $298.62M | $4.60 | — |
News headlines (Yahoo Finance, 1h cache)
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
2026-07-29 20:30 · Yahoo
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
2026-07-16 20:30 · Yahoo
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
2026-07-15 20:30 · Yahoo
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
2026-07-10 20:30 · Yahoo
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy
2026-07-08 00:22 · Yahoo
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
2026-07-07 20:30 · Yahoo
Here’s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA)
2026-07-03 13:13 · Yahoo
Insomnia Market Witnesses Robust Growth During the Forecast Period (2026-2036) with Emerging Orexin Receptor Antagonists and Melatonin Receptor Agonist | DelveInsight
2026-06-18 16:31 · Yahoo
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
2026-05-27 11:00 · Yahoo
Charcot-Marie-Tooth Disease Market Growth to Accelerate Significantly During the Forecast Period (2026-2036) Driven by the Launch of Emerging Disease-Modifying Therapies | DelveInsight
2026-05-21 09:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.